Viatris Inc


SKU: VTRS Category:


This is our first report on global healthcare giant, Viatris. The company delivered a disappointing set of results for the last quarter, missing Wall Street expectations in terms of revenues as well as earnings given the numerous industry headwinds, especially inflationary pressures. The company had an interesting set of developments which included a strategic agreement to sell off their biosimilars business to Biocon Biologics. Besides, Tyrvaya’s clinical development for new indications, like neurotrophic keratopathy, is currently ongoing. Due to the Famy Life Sciences acquisition, five more front-of-the-eye programs in diverse indications that are in Phase III or are ready for Phase III will be added. By 2028, they project that Tyrvaya and these front-of-the-eye ophthalmology assets would likely generate significant annual revenue. The management appears to have a clear path to return their company to top-line and bottom-line growth for 2024 and beyond along with the necessary financial flexibility to manage debt levels and to further business development. We initiate coverage on the stock of Viatris with a ‘Hold’ rating.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!